{"pmid":32426212,"pmcid":"PMC7231734","title":"Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.","text":["Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.","The World Health Organization has declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, as pandemic. There is currently a lack of knowledge about the antibody response elicited from SARS-CoV-2 infection. One major immunological question concerns antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by analyzing plasma from patients infected by SARS-CoV-2 or SARS-CoV, and from infected or immunized mice. Our results show that, while cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of non-neutralizing antibody response to conserved epitopes in the spike. Whether such low or non-neutralizing antibody response leads to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding antigenicity differences between SARS-CoV-2 and SARS-CoV, but also has implications for immunogen design and vaccine development.","Cell Rep","Lv, Huibin","Wu, Nicholas C","Tak-Yin Tsang, Owen","Yuan, Meng","Perera, Ranawaka A P M","Leung, Wai Shing","So, Ray T Y","Chun Chan, Jacky Man","Yip, Garrick K","Hong Chik, Thomas Shiu","Wang, Yiquan","Chung Choi, Chris Yau","Lin, Yihan","Ng, Wilson W","Zhao, Jincun","Poon, Leo L M","Peiris, J S Malik","Wilson, Ian A","Mok, Chris K P","32426212"],"abstract":["The World Health Organization has declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, as pandemic. There is currently a lack of knowledge about the antibody response elicited from SARS-CoV-2 infection. One major immunological question concerns antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by analyzing plasma from patients infected by SARS-CoV-2 or SARS-CoV, and from infected or immunized mice. Our results show that, while cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of non-neutralizing antibody response to conserved epitopes in the spike. Whether such low or non-neutralizing antibody response leads to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding antigenicity differences between SARS-CoV-2 and SARS-CoV, but also has implications for immunogen design and vaccine development."],"journal":"Cell Rep","authors":["Lv, Huibin","Wu, Nicholas C","Tak-Yin Tsang, Owen","Yuan, Meng","Perera, Ranawaka A P M","Leung, Wai Shing","So, Ray T Y","Chun Chan, Jacky Man","Yip, Garrick K","Hong Chik, Thomas Shiu","Wang, Yiquan","Chung Choi, Chris Yau","Lin, Yihan","Ng, Wilson W","Zhao, Jincun","Poon, Leo L M","Peiris, J S Malik","Wilson, Ian A","Mok, Chris K P"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426212","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.celrep.2020.107725","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667352728782766083,"score":9.490897,"similar":[{"pmid":32415260,"title":"Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.","text":["Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.","Coronavirus disease 2019 (COVID-19), caused by the novel human coronavirus SARS-CoV-2, is currently a major threat to public health worldwide. The viral spike protein binds the host receptor angiotensin-converting enzyme 2 (ACE2) via the receptor-binding domain (RBD), and thus is believed to be a major target to block viral entry. Both SARS-CoV-2 and SARS-CoV share this mechanism. Here we functionally analyzed the key amino acid residues located within receptor binding motif of RBD that may interact with human ACE2 and available neutralizing antibodies. The in vivo experiments showed that immunization with either the SARS-CoV RBD or SARS-CoV-2 RBD was able to induce strong clade-specific neutralizing antibodies in mice; however, the cross-neutralizing activity was much weaker, indicating that there are distinct antigenic features in the RBDs of the two viruses. This finding was confirmed with the available neutralizing monoclonal antibodies against SARS-CoV or SARS-CoV-2. It is worth noting that a newly developed SARS-CoV-2 human antibody, HA001, was able to neutralize SARS-CoV-2, but failed to recognize SARS-CoV. Moreover, the potential epitope residues of HA001 were identified as A475 and F486 in the SARS-CoV-2 RBD, representing new binding sites for neutralizing antibodies. Overall, our study has revealed the presence of different key epitopes between SARS-CoV and SARS-CoV-2, which indicates the necessity to develop new prophylactic vaccine and antibody drugs for specific control of the COVID-19 pandemic although the available agents obtained from the SARS-CoV study are unneglectable.","Cell Mol Immunol","Yi, Chunyan","Sun, Xiaoyu","Ye, Jing","Ding, Longfei","Liu, Meiqin","Yang, Zhuo","Lu, Xiao","Zhang, Yaguang","Ma, Liyang","Gu, Wangpeng","Qu, Aidong","Xu, Jianqing","Shi, Zhengli","Ling, Zhiyang","Sun, Bing","32415260"],"abstract":["Coronavirus disease 2019 (COVID-19), caused by the novel human coronavirus SARS-CoV-2, is currently a major threat to public health worldwide. The viral spike protein binds the host receptor angiotensin-converting enzyme 2 (ACE2) via the receptor-binding domain (RBD), and thus is believed to be a major target to block viral entry. Both SARS-CoV-2 and SARS-CoV share this mechanism. Here we functionally analyzed the key amino acid residues located within receptor binding motif of RBD that may interact with human ACE2 and available neutralizing antibodies. The in vivo experiments showed that immunization with either the SARS-CoV RBD or SARS-CoV-2 RBD was able to induce strong clade-specific neutralizing antibodies in mice; however, the cross-neutralizing activity was much weaker, indicating that there are distinct antigenic features in the RBDs of the two viruses. This finding was confirmed with the available neutralizing monoclonal antibodies against SARS-CoV or SARS-CoV-2. It is worth noting that a newly developed SARS-CoV-2 human antibody, HA001, was able to neutralize SARS-CoV-2, but failed to recognize SARS-CoV. Moreover, the potential epitope residues of HA001 were identified as A475 and F486 in the SARS-CoV-2 RBD, representing new binding sites for neutralizing antibodies. Overall, our study has revealed the presence of different key epitopes between SARS-CoV and SARS-CoV-2, which indicates the necessity to develop new prophylactic vaccine and antibody drugs for specific control of the COVID-19 pandemic although the available agents obtained from the SARS-CoV study are unneglectable."],"journal":"Cell Mol Immunol","authors":["Yi, Chunyan","Sun, Xiaoyu","Ye, Jing","Ding, Longfei","Liu, Meiqin","Yang, Zhuo","Lu, Xiao","Zhang, Yaguang","Ma, Liyang","Gu, Wangpeng","Qu, Aidong","Xu, Jianqing","Shi, Zhengli","Ling, Zhiyang","Sun, Bing"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415260","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41423-020-0458-z","keywords":["sars-cov-2","cross-neutralizing antibody","receptor binding motif","spike protein","substitution mutation"],"locations":["vivo"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666991242711400449,"score":477.81387},{"pmid":32245784,"pmcid":"PMC7164391","title":"A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV.","text":["A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV.","The outbreak of COVID-19 caused by SARS-CoV-2 virus has now become a pandemic, but there is currently very little understanding of the antigenicity of the virus. We therefore determined the crystal structure of CR3022, a neutralizing antibody previously isolated from a convalescent SARS patient, in complex with the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein to 3.1 A. CR3022 targets a highly conserved epitope, distal from the receptor-binding site, that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV. Structural modeling further demonstrates that the binding epitope can only be accessed by CR3022 when at least two RBD on the trimeric S protein are in the \"up\" conformation and slightly rotated. Overall, this study provides molecular insights into antibody recognition of SARS-CoV-2.","Science","Yuan, Meng","Wu, Nicholas C","Zhu, Xueyong","Lee, Chang-Chun D","So, Ray T Y","Lv, Huibin","Mok, Chris K P","Wilson, Ian A","32245784"],"abstract":["The outbreak of COVID-19 caused by SARS-CoV-2 virus has now become a pandemic, but there is currently very little understanding of the antigenicity of the virus. We therefore determined the crystal structure of CR3022, a neutralizing antibody previously isolated from a convalescent SARS patient, in complex with the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein to 3.1 A. CR3022 targets a highly conserved epitope, distal from the receptor-binding site, that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV. Structural modeling further demonstrates that the binding epitope can only be accessed by CR3022 when at least two RBD on the trimeric S protein are in the \"up\" conformation and slightly rotated. Overall, this study provides molecular insights into antibody recognition of SARS-CoV-2."],"journal":"Science","authors":["Yuan, Meng","Wu, Nicholas C","Zhu, Xueyong","Lee, Chang-Chun D","So, Ray T Y","Lv, Huibin","Mok, Chris K P","Wilson, Ian A"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32245784","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1126/science.abb7269","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138492059516930,"score":433.4236},{"pmid":32422645,"title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.","text":["Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.","SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020(1,2). Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of an individual who was infected with SARS-CoV in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309- and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease.","Nature","Pinto, Dora","Park, Young-Jun","Beltramello, Martina","Walls, Alexandra C","Tortorici, M Alejandra","Bianchi, Siro","Jaconi, Stefano","Culap, Katja","Zatta, Fabrizia","De Marco, Anna","Peter, Alessia","Guarino, Barbara","Spreafico, Roberto","Cameroni, Elisabetta","Case, James Brett","Chen, Rita E","Havenar-Daughton, Colin","Snell, Gyorgy","Telenti, Amalio","Virgin, Herbert W","Lanzavecchia, Antonio","Diamond, Michael S","Fink, Katja","Veesler, David","Corti, Davide","32422645"],"abstract":["SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020(1,2). Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of an individual who was infected with SARS-CoV in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309- and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease."],"journal":"Nature","authors":["Pinto, Dora","Park, Young-Jun","Beltramello, Martina","Walls, Alexandra C","Tortorici, M Alejandra","Bianchi, Siro","Jaconi, Stefano","Culap, Katja","Zatta, Fabrizia","De Marco, Anna","Peter, Alessia","Guarino, Barbara","Spreafico, Roberto","Cameroni, Elisabetta","Case, James Brett","Chen, Rita E","Havenar-Daughton, Colin","Snell, Gyorgy","Telenti, Amalio","Virgin, Herbert W","Lanzavecchia, Antonio","Diamond, Michael S","Fink, Katja","Veesler, David","Corti, Davide"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422645","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41586-020-2349-y","e_drugs":["Polysaccharides"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667254896791912448,"score":428.31354},{"pmid":32425270,"pmcid":"PMC7231725","title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.","text":["Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.","The COVID-19 pandemic urgently needs therapeutic and prophylactic interventions. Here we report the rapid identification of SARS-CoV-2 neutralizing antibodies by high-throughput single-cell RNA and VDJ sequencing of antigen-enriched B cells from 60 convalescent patients. From 8,558 antigen-binding IgG1(+) clonotypes, 14 potent neutralizing antibodies were identified with the most potent one, BD-368-2, exhibiting an IC50 of 1.2 ng/mL and 15 ng/mL against pseudotyped and authentic SARS-CoV-2, respectively. BD-368-2 also displayed strong therapeutic and prophylactic efficacy in SARS-CoV-2-infected hACE2-transgenic mice. Additionally, the 3.8A Cryo-EM structure of a neutralizing antibody in complex with the spike-ectodomain trimer revealed the antibody's epitope overlaps with the ACE2 binding site. Moreover, we demonstrated that SARS-CoV-2 neutralizing antibodies could be directly selected based on similarities of their predicted CDR3H structures to those of SARS-CoV neutralizing antibodies. Altogether, we showed that human neutralizing antibodies could be efficiently discovered by high-throughput single B-cell sequencing in response to pandemic infectious diseases.","Cell","Cao, Yunlong","Su, Bin","Guo, Xianghua","Sun, Wenjie","Deng, Yongqiang","Bao, Linlin","Zhu, Qinyu","Zhang, Xu","Zheng, Yinghui","Geng, Chenyang","Chai, Xiaoran","He, Runsheng","Li, Xiaofeng","Lv, Qi","Zhu, Hua","Deng, Wei","Xu, Yanfeng","Wang, Yanjun","Qiao, Luxin","Tan, Yafang","Song, Liyang","Wang, Guopeng","Du, Xiaoxia","Gao, Ning","Liu, Jiangning","Xiao, Junyu","Su, Xiao-Dong","Du, Zongmin","Feng, Yingmei","Qin, Chuan","Qin, Chengfeng","Jin, Ronghua","Xie, X Sunney","32425270"],"abstract":["The COVID-19 pandemic urgently needs therapeutic and prophylactic interventions. Here we report the rapid identification of SARS-CoV-2 neutralizing antibodies by high-throughput single-cell RNA and VDJ sequencing of antigen-enriched B cells from 60 convalescent patients. From 8,558 antigen-binding IgG1(+) clonotypes, 14 potent neutralizing antibodies were identified with the most potent one, BD-368-2, exhibiting an IC50 of 1.2 ng/mL and 15 ng/mL against pseudotyped and authentic SARS-CoV-2, respectively. BD-368-2 also displayed strong therapeutic and prophylactic efficacy in SARS-CoV-2-infected hACE2-transgenic mice. Additionally, the 3.8A Cryo-EM structure of a neutralizing antibody in complex with the spike-ectodomain trimer revealed the antibody's epitope overlaps with the ACE2 binding site. Moreover, we demonstrated that SARS-CoV-2 neutralizing antibodies could be directly selected based on similarities of their predicted CDR3H structures to those of SARS-CoV neutralizing antibodies. Altogether, we showed that human neutralizing antibodies could be efficiently discovered by high-throughput single B-cell sequencing in response to pandemic infectious diseases."],"journal":"Cell","authors":["Cao, Yunlong","Su, Bin","Guo, Xianghua","Sun, Wenjie","Deng, Yongqiang","Bao, Linlin","Zhu, Qinyu","Zhang, Xu","Zheng, Yinghui","Geng, Chenyang","Chai, Xiaoran","He, Runsheng","Li, Xiaofeng","Lv, Qi","Zhu, Hua","Deng, Wei","Xu, Yanfeng","Wang, Yanjun","Qiao, Luxin","Tan, Yafang","Song, Liyang","Wang, Guopeng","Du, Xiaoxia","Gao, Ning","Liu, Jiangning","Xiao, Junyu","Su, Xiao-Dong","Du, Zongmin","Feng, Yingmei","Qin, Chuan","Qin, Chengfeng","Jin, Ronghua","Xie, X Sunney"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425270","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.cell.2020.05.025","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667252837804933122,"score":415.12253},{"pmid":32065055,"pmcid":"PMC7048180","title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.","text":["Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.","The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. These results suggest that CR3022 may have the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019-nCoV infections. Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD.","Emerg Microbes Infect","Tian, Xiaolong","Li, Cheng","Huang, Ailing","Xia, Shuai","Lu, Sicong","Shi, Zhengli","Lu, Lu","Jiang, Shibo","Yang, Zhenlin","Wu, Yanling","Ying, Tianlei","32065055"],"abstract":["The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. These results suggest that CR3022 may have the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019-nCoV infections. Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD."],"journal":"Emerg Microbes Infect","authors":["Tian, Xiaolong","Li, Cheng","Huang, Ailing","Xia, Shuai","Lu, Sicong","Shi, Zhengli","Lu, Lu","Jiang, Shibo","Yang, Zhenlin","Wu, Yanling","Ying, Tianlei"],"date":"2020-02-18T11:00:00Z","year":2020,"_id":"32065055","source":"PubMed","week":"20208|Feb 17 - Feb 23","doi":"10.1080/22221751.2020.1729069","keywords":["2019-ncov","ace2","rbd","sars-cov","monoclonal antibody"],"link_comment_in":"32132669","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490837925889,"score":409.66058}]}